用mycophenolate mofetil替代氨酸抑制剂在肝移植患者的功能障碍:一个随机对照研究
H J Schlitt1, A Barkmann, K H Böker
1Klinik für Viszeral und Transplantationschirurgie, Medizinische Hochschule Hannover, Germany. schlitt.hans@mh-hannover.de
Lancet (London, England)
|September 18, 2001
概括
在肝移植患者中,从氨酸抑制剂 (CNI) 转换为mycophenolate mofetil改善了功能和血压. 然而,这种变化增加了移植排斥的风险.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 移植医学 移植医学
- 免疫抑制是一种免疫抑制.
背景情况:
- 在肝移植患者的长期氨酸抑制剂 (CNI) 治疗中,经常导致功能障碍.
- 评估用mycophenolate mofetil替代CNI的安全性和有效性对于管理移植后并发症至关重要.
研究的目的:
- 评估用mycophenolate mofetil替代氨酸抑制剂 (CNI) 对肝移植患者功能的影响.
- 为了评估这种免疫抑制剂的安全性和有效性,改变治疗方案.
主要方法:
- 一项随机研究涉及28名肝移植接受者,患有功能障碍.
- 患者被分为两组:一组用mycophenolate mofetil替换了CNI,而对照组继续进行CNI治疗.
- 对功能,血压,尿酸,血脂和移植功能进行了6个月的监测.
主要成果:
- 与对照组相比,mycophenolate mofetil组的血清肌素水平显著下降 (平均差异为41.3微摩尔/升).
- 缩和透气血压,血清尿酸也显示在研究小组显著减少.
- 在mycophenolate mofetil组中发生了三次急性移植排斥,而在对照组中没有观察到.
结论:
- 用mycophenolate mofetil替换CNI可以提高功能,降低血压,并降低肝移植患者的尿酸水平.
- 用mycophenolate mofetil单一治疗与急性移植排斥的风险增加有关.
相关概念视频
Tissue Transplantation
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Kidney Transplant I: Introduction
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...


